Switching to Biosimilar Infliximab Is Safe and Effective

Summary and Comment |
June 6, 2017

Switching to Biosimilar Infliximab Is Safe and Effective

  1. Douglas K. Rex, MD

Patients on infliximab for a variety of indications had similar outcomes with infliximab or its biosimilar CT-P13 in a 1-year trial.

  1. Douglas K. Rex, MD

Biosimilars are effective in inducing remission in inflammatory bowel disease, but the current randomized trial is the first to compare switching patients who were stable on infliximab to a biosimilar (FDA-approved CT-P13).

The double-blind, phase IV study included 482 patients, of whom 32% had Crohn disease, 19% ulcerative colitis, 19% spondyloarthritis, 16% rheumatoid arthritis, 7% chronic plaque psoriasis, and 6% psoriatic arthritis.

During the one-year study, disease worsening occurred in 26% on infliximab and 30% on biosimilar (no difference). Rates of adverse events were similar between groups.

Comment

This study indicates that at least for infliximab, patients on stable chronic therapy can be switched to biosimilar without an increased risk for loss of response.

Editor Disclosures at Time of Publication

  • Disclosures for Douglas K. Rex, MD at time of publication Consultant/Advisory board Olympus Corporation America; Boston Scientific Speaker’s bureau Boston Scientific Grant/Research support Medtronic; Boston Scientific; Colonary Solutions; Paion Medical; Medivators; Braintree Laboratories Editorial boards World Journal of Gastroenterology; The Journal of Clinical Gastroenterology; Techniques in Gastrointestinal Endoscopy; Gastroenterology & Hepatology; Expert Review of Gastroenterology & Hepatology; Medscape Gastroenterology; World Journal of Gastrointestinal Pharmacology and Therapeutics; Annals of Gastroenterology & Hepatology; World Journal of Gastrointestinal Oncology; Comparative Effectiveness Research; Journal of Anesthesia & Clinical Research; Gastroenterology; World Journal of Gastrointestinal Pathophysiology; Gastroenterology Research and Practice; GI & Hepatology News; Gastroenterology Report; Clinical Epidemiology Reviews; JSM Gastroenterology and Hepatology; GI Journal Watch; Austin Journal of Gastroenterology; World Journal of Gastrointestinal Pharmacology & Therapeutics Leadership positions in professional societies American Society for Gastrointestinal Endoscopy (Councilor); US Multi-Society Task Force (AGA, ACG, ASGE) (Chair)

Citation(s):

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.